ACY-1083

• UNSPSC Description:

  ACY-1083 is a selective and brain-penetrating HDAC6 inhibitor with an IC50 of 3 nM and is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy[1].

• Target Antigen:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ACY-1083.html

• Purity:

  99.80

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  FC(CC1)(F)CCC1(NC2=NC=C(C(NO)=O)C=N2)C3=CC=CC=C3

• Molecular Weight:

  348.35

• References & Citations:

  [1]Krukowski K, et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain. 2017 Jun;158(6):1126-1137.|[2]Vahagn C Nikolian, et al. Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2019 Feb;86(2):232-239.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  1708113-43-2